WallStreetZenWallStreetZen

NASDAQ: ABUS
Arbutus Biopharma Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ABUS

Based on 1 analyst offering 12 month price targets for Arbutus Biopharma Corp

Min Forecast
$5.00+10.86%
Avg Forecast
$5.00+10.86%
Max Forecast
$5.00+10.86%

Should I buy or sell ABUS stock?

Based on 1 analyst offering ratings for Arbutus Biopharma Corp.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ABUS stock forecasts and price targets.

ABUS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-11

1 of 1

Forecast return on equity

Is ABUS forecast to generate an efficient return?

Company
-32.34%
Industry
93.13%
Market
-61.61%
ABUS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABUS forecast to generate an efficient return on assets?

Company
-25.99%
Industry
35.76%
ABUS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABUS earnings per share forecast

What is ABUS's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.18
Avg 2 year Forecast
-$0.17

ABUS revenue forecast

What is ABUS's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$14.2M-7.89%
Avg 2 year Forecast
$1.1M-92.86%
ABUS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABUS revenue growth forecast

How is ABUS forecast to perform vs Biotechnology companies and vs the US market?

Company
-29.69%
Industry
89.75%
Market
11.9%
ABUS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABUS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABUS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABUS$4.47$5.00+11.86%Strong Buy
GYRE$8.87$17.00+91.66%Strong Buy
MRVI$3.37$4.00+18.69%Buy
VALN$10.50$15.50+47.62%Strong Buy
PVLA$76.31$76.11-0.26%Strong Buy
View Top Biotech Stocks

Arbutus Biopharma Stock Forecast FAQ

Is Arbutus Biopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ABUS) stock is to Strong Buy ABUS stock.

Out of 1 analyst, 1 (100%) are recommending ABUS as a Strong Buy, 0 (0%) are recommending ABUS as a Buy, 0 (0%) are recommending ABUS as a Hold, 0 (0%) are recommending ABUS as a Sell, and 0 (0%) are recommending ABUS as a Strong Sell.

If you're new to stock investing, here's how to buy Arbutus Biopharma stock.

What is ABUS's earnings growth forecast for 2025-2026?

(NASDAQ: ABUS) Arbutus Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.54%.

Arbutus Biopharma's earnings in 2025 is -$54,252,000.On average, 1 Wall Street analyst forecast ABUS's earnings for 2025 to be -$34,505,765, with the lowest ABUS earnings forecast at -$34,505,765, and the highest ABUS earnings forecast at -$34,505,765.

In 2026, ABUS is forecast to generate -$32,588,778 in earnings, with the lowest earnings forecast at -$32,588,778 and the highest earnings forecast at -$32,588,778.

What is ABUS's revenue growth forecast for 2025-2026?

(NASDAQ: ABUS) Arbutus Biopharma's forecast annual revenue growth rate of -29.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 87.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.62%.

Arbutus Biopharma's revenue in 2025 is $15,416,000.On average, 1 Wall Street analysts forecast ABUS's revenue for 2025 to be $2,722,121,469, with the lowest ABUS revenue forecast at $2,722,121,469, and the highest ABUS revenue forecast at $2,722,121,469.

In 2026, ABUS is forecast to generate $210,868,565 in revenue, with the lowest revenue forecast at $210,868,565 and the highest revenue forecast at $210,868,565.

What is ABUS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ABUS) forecast ROA is -25.99%, which is lower than the forecast US Biotechnology industry average of 35.85%.

What is ABUS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ABUS price target, the average ABUS price target is $5.00, with the highest ABUS stock price forecast at $5.00 and the lowest ABUS stock price forecast at $5.00.

The Wall Street analyst predicted that Arbutus Biopharma's share price could reach $5.00 by Aug 11, 2026. The average Arbutus Biopharma stock price prediction forecasts a potential upside of 11.86% from the current ABUS share price of $4.47.

What is ABUS's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ABUS) Arbutus Biopharma's current Earnings Per Share (EPS) is -$0.29. On average, analysts forecast that ABUS's EPS will be -$0.18 for 2025, with the lowest EPS forecast at -$0.18, and the highest EPS forecast at -$0.18. In 2026, ABUS's EPS is forecast to hit -$0.17 (min: -$0.17, max: -$0.17).

What is ABUS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ABUS) forecast ROE is -32.34%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.